CINQAERO® is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.1
*Data from two randomised, double-blind, placebo-controlled clinical trials (n=953) in a targeted patient population with inadequately controlled asthma and elevated blood eosinophils (≥400 cells/μL). Patients received either placebo (n=476) or CINQAERO® (n=477). Both treatments were added to standard of care.1,2
[Pooled analysis of two studies where patients with blood eosinophils ≥400 cells/µL and one or more exacerbations in the previous year were randomised to reslizumab 3mg/kg by i.v. infusion (n=477) or placebo (n=476) every four weeks.]
CINQAERO® is provided as a concentrate for solution for infusion, in a single-use vial.1
Reslizumab is a humanised monoclonal antibody that binds specifically to interleukin-5, a major cytokine responsible for the differentiation, maturation, recruitment and activation of eosinophils - which have a role in inadequately controlled asthma.1,2
CINQAERO® targets IL-5 to reduce eosinophilic airway inflammation and reduce blood eosinophils.1,2
Teva Pharma B.V.
Marketing Authorisation number(s)
1. CINQAERO® Summary of Product Characteristics. Teva Pharmaceuticals Europe B.V.
2. Castro M, Zangrilli J, Wechsler ME et al. Lancet Respir Med, 2015; 3: 355-66.
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.